BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone919-582-9050
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$55.64 million
Profitability
Miscellaneous
Employees164
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable
BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions
What is BioDelivery Sciences International's stock symbol?
BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."
How were BioDelivery Sciences International's earnings last quarter?
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.34. The specialty pharmaceutical company had revenue of $30.31 million for the quarter, compared to analyst estimates of $28.86 million. BioDelivery Sciences International had a negative net margin of 22.11% and a negative return on equity of 8.80%. View BioDelivery Sciences International's Earnings History.
When is BioDelivery Sciences International's next earnings date?
What price target have analysts set for BDSI?
6 brokers have issued twelve-month price targets for BioDelivery Sciences International's shares. Their forecasts range from $5.00 to $8.00. On average, they anticipate BioDelivery Sciences International's share price to reach $6.80 in the next twelve months. This suggests a possible upside of 10.6% from the stock's current price. View Analyst Price Targets for BioDelivery Sciences International.
What is the consensus analysts' recommendation for BioDelivery Sciences International?
What are Wall Street analysts saying about BioDelivery Sciences International stock?
Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
- 1. According to Zacks Investment Research, "BioDelivery reported encouraging first-quarter results wherein earnings and sales surpassed the respective estimates. The company secured improved positioning in several managed care contracts, providing preferred access to Belbuca. The company’s efforts have brought 115 million patients under preferred coverage so far in 2019, having started 2018 with 7 million. The company’s efforts boosted the drug’s sales and the momentum is expected to continue in 2019. Belbuca’s prescriptions grew sequentially in the past few quarters. The acquisition of U.S. rights of Symproic strengthened the chronic pain portfolio. BioDelivery’s shares have outperformed the industry so far this year. However, given the lackluster performance of Bunavail, BioDelivery has decided to reduce spending on the drug. The company’s portfolio and its pipeline may face severe competition as these target a highly genericized and crowded market." (5/21/2019)
- 2. Cantor Fitzgerald analysts commented, ". Post BDSI’s recent acquisition of U.S. commercial rights to Symproic, and equity raise, we are updating our model and reiterating our Overweight rating and 12-month price target of $8. BDSI has built a strong commercial team around Belbuca, and the acquisition leverages the company’s commercial strengths, and footprint, to grow its portfolio. We view the acquisition of Symproic as a positive as it diversifies the company’s revenue away from a single product, Belbuca, and can add a meaningful revenue contribution of $75MM + without the need for any significant increase in spending." (4/16/2019)
- 3. HC Wainwright analysts commented, "Our $6 12-month target (from $5) is based on a DCF reflecting strong Belbuca growth to nearly $180M by 2022, company cash-flow breakeven by end-2019, and overall profitability in 2020. Our DCF reflects a 10% WACC discount and negative -15% terminal value beyond 2026, and includes 90M fully diluted shares vs. currently reported 70M) to account for, among other shares, the substantial dilution from convertible preferred series B shares that were issued in the 2018 $50M financing ($1.80/share conversion price)." (3/15/2019)
Has BioDelivery Sciences International been receiving favorable news coverage?
Headlines about BDSI stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioDelivery Sciences International earned a media sentiment score of -3.4 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for BioDelivery Sciences International.
Are investors shorting BioDelivery Sciences International?
BioDelivery Sciences International saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 3,580,000 shares, a decrease of 14.8% from the September 30th total of 4,200,000 shares. Based on an average daily trading volume, of 705,300 shares, the short-interest ratio is currently 5.1 days. Currently, 4.4% of the company's stock are sold short. View BioDelivery Sciences International's Current Options Chain.
Who are some of BioDelivery Sciences International's key competitors?
Some companies that are related to BioDelivery Sciences International include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).
What other stocks do shareholders of BioDelivery Sciences International own?
Who are BioDelivery Sciences International's key executives?
BioDelivery Sciences International's management team includes the folowing people:
- Mr. Herm Cukier, CEO & Director (Age 52)
- Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 54)
- Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 50)
- Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 58)
- Mr. Ernest Robert De Paolantonio CPA, MBA, Exec. Officer (Age 66)
Who are BioDelivery Sciences International's major shareholders?
BioDelivery Sciences International's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (2.33%), Emerald Mutual Fund Advisers Trust (2.17%), 1492 Capital Management LLC (0.87%), Mackay Shields LLC (0.68%), Essex Investment Management Co. LLC (0.40%) and California Public Employees Retirement System (0.33%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, Mark A Sirgo and Paolantonio Ernest Robert De. View Institutional Ownership Trends for BioDelivery Sciences International.
Which institutional investors are selling BioDelivery Sciences International stock?
BDSI stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Essex Investment Management Co. LLC and 1492 Capital Management LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, Mark A Sirgo and Paolantonio Ernest Robert De. View Insider Buying and Selling for BioDelivery Sciences International.
Which institutional investors are buying BioDelivery Sciences International stock?
BDSI stock was acquired by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Systematic Financial Management LP, Brinker Capital Inc., Nisa Investment Advisors LLC, California Public Employees Retirement System and NEXT Financial Group Inc. View Insider Buying and Selling for BioDelivery Sciences International.
How do I buy shares of BioDelivery Sciences International?
Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BioDelivery Sciences International's stock price today?
One share of BDSI stock can currently be purchased for approximately $6.15.
How big of a company is BioDelivery Sciences International?
BioDelivery Sciences International has a market capitalization of $550.57 million and generates $55.64 million in revenue each year. The specialty pharmaceutical company earns $-33,870,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. BioDelivery Sciences International employs 164 workers across the globe.View Additional Information About BioDelivery Sciences International.
What is BioDelivery Sciences International's official website?
How can I contact BioDelivery Sciences International?
BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]
MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
